GlassScriptPhysician profile
Sunaina Devi Ravuru
NPI 1699346775
$1,093.82
in general payments reported to CMS, 2019-2025
9 companies · $236 in 2025
The $236 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $199 · 2023: $210 · 2024: $449 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $697 · Education: $198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $697.10 |
| Education | $197.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $297.36 | 2024-2025 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $266.07 | 2022-2025 | Airsupra, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $158.17 | 2022-2023 | Nucala |
| Baxter Healthcare | $126.04 | 2023-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Visivest Airway Clearance System |
| Bayer Healthcare Pharmaceuticals INC. | $107.85 | 2022-2023 | |
| Lilly USA, LLC | $47.01 | 2023 | Jardiance |
| Philips North America LLC | $41.22 | 2024 | (Ak6) Vest Therapy |
| Novo Nordisk INC | $31.02 | 2025 | Wegovy, Saxenda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.08 | 2025 | Jascayd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunaina Ravuru listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.